Neoantigens Vaccines Can Bridge the Treatment Gap by Training the Immune System to Recognize Tumor Cells
As per BIS Research analysis, the neoantigen
cancer vaccine market is projected to reach $1826.1 million by 2030 from $227.1
million in 2023, at a CAGR of 34.69%. Growth in this market is expected to be driven
by the ever-rising patient pool of different cancers and significant investment
in research for development for cancer neoantigen vaccines to fill in the
current treatment gaps. However, there are significant challenges that are
restraining the market growth. These challenges include the high cost of therapy
(personalized cancer vaccines), manufacturing complications, and lack of therapeutic
biomarkers and assays.
The market is still at the nascent phase with
more than two-thirds of the neovaccines in the early stages of development.
However, few neovaccines companies such as OSE Immunotherapeutics, Immunovative
Therapeutics, Medigene, and Roche have positioned themselves to launch their
neovaccines in the market within the upcoming years. That being said, the
neovaccine market is expected to gain momentum post-2023 owing to the expected initial
launch of OSE Immunotherapeutics late-stage asset Tedopi in the market.
Expected Stature of Key Players
As per BIS Research analysis, two late
stage companies OSE Immunotherapeutics and Immunovative Therapies are expected
to be highly disruptive owing to the recently reported positive outcomes from
the ongoing clinical studies of their investigational neovaccines. In the long
run, Moderna Therapeutics, Genocea and Gritstone oncology are expected to gain
a significant share owing to their innovative technologies and neoantigen
predication approaches.
Current Treatment Gaps
The current immunotherapeutic standard of
care (SOC) regimens come with the cost of high toxicity profiles with several
reported instances, where cancer patients do not respond to the provided
treatment or in some cases are in-eligible to get the current standard of
cares. To redress these cases, the emerging opportunity of vaccinating patients
against cancer neoantigens can change the treatment unresponsive cold tumors
into hot tumors by training the immune system to recognize tumor cells as a
foreign entity.
In this manner my colleague Wesley Virgin's story begins with this SHOCKING AND CONTROVERSIAL VIDEO.
ReplyDeleteAs a matter of fact, Wesley was in the army-and soon after leaving-he found hidden, "SELF MIND CONTROL" secrets that the government and others used to obtain everything they want.
These are the EXACT same tactics many celebrities (notably those who "come out of nothing") and top business people used to become rich and successful.
You probably know how you use only 10% of your brain.
Really, that's because the majority of your BRAINPOWER is UNCONSCIOUS.
Maybe this thought has even taken place IN YOUR very own mind... as it did in my good friend Wesley Virgin's mind seven years ago, while driving an unregistered, garbage bucket of a car without a driver's license and with $3 in his pocket.
"I'm so frustrated with going through life paycheck to paycheck! When will I finally succeed?"
You've taken part in those conversations, ain't it right?
Your success story is waiting to be written. Go and take a leap of faith in YOURSELF.
Watch Wesley Virgin's Video Now!